Provide feedbackProvide feedback

« Back

Oramed's IND for oral insulin capsule granted FDA clearance

Wednesday, May 22 2013 | Comments
Evidence Grade 0 What's This?
The Food and Drug Administration approved Oramed Pharmaceuticals Inc.'s Investigational New Drug application for ORMD-0801, an orally ingestible insulin capsule.

The firm will begin studies of ORMD-0801 for the treatment of early stages of type 2 diabetes, when it can still slow the rate of degeneration of the disease by providing additional insulin to the body and allowing pancreatic respite.

Oramed noted that orally administered insulin has the potential benefit of improving patient compliance and it can mimic insulin's natural location and gradients in the body by first passing through the liver before entering the bloodstream.

Print  |  E-mail

Comments

Be the first to write a comment for this article!

You must be logged in to post a comment.